Towards a framework for treatment effectiveness in schizophrenia

References

• American Psychiatric AssociationPractice guideline for the treatment of patients with schizophrenia2nd ed2004
   Google Scholar
• FalkaiPWobrockTLiebermanJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophreniaWorld J Biol Psychiatry20067154016509050
   PubMed Web of Science ®Google Scholar
• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry2004161341442514992963
   PubMed Web of Science ®Google Scholar
• HealDJGosdenJJacksonHCCheethamSCSmithSLMetabolic consequences of antipsychotic therapy: preclinical and clinical perspectives on diabetes, diabetic ketoacidosis, and obesityHandb Exp Pharmacol201221213516423129331
   PubMedGoogle Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• RichelsonESouderTBinding of antipsychotic drugs to human brain receptors focus on newer generation compoundsLife Sci2000681293911132243
   PubMed Web of Science ®Google Scholar
• NasrallahHAAtypical antipsychotic-induced metabolic side effects: insights from receptor-binding profilesMol Psychiatry2008131273517848919
   PubMed Web of Science ®Google Scholar
• JohnsenEJørgensenHAEffectiveness of second generation antipsychotics: a systematic review of randomized trialsBMC Psychiatry200883118439263
   PubMed Web of Science ®Google Scholar
• KahnRSFleischhackerWWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• ZimbroffDLManagement of acute psychosis: from emergency to stabilizationCNS Spectr2003811 Suppl 2101514978452
   PubMed Web of Science ®Google Scholar
• CaseyDELong-term treatment goals: enhancing healthy outcomesCNS Spectr2003811 Suppl 2262814978456
   PubMed Web of Science ®Google Scholar
• KeshavanMSNasrallahHATandonRSchizophrenia, “Just the Facts” 6. Moving ahead with the schizophrenia concept: from the elephant to the mouseSchizophr Res20111271–331321316923
   PubMed Web of Science ®Google Scholar
• StroupTSMcEvoyJPSwartzMSThe National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developmentSchizophr Bull2003291153112908658
   PubMed Web of Science ®Google Scholar
• DossenbachMErolAel MahfoudKMEffectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidolJ Clin Psychiatry200465331232115096069
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETNovickDEffectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand2005111322023115701107
   PubMed Web of Science ®Google Scholar
• JonesPBBarnesTRDaviesLRandomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)Arch Gen Psychiatry200663101079108717015810
   PubMed Web of Science ®Google Scholar
• LewisSWBarnesTRDaviesLRandomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophreniaSchizophr Bull200632471572316540702
   PubMed Web of Science ®Google Scholar
• TandonRMarcusRNStockEGA prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)Schizophr Res2006841778916483745
   PubMed Web of Science ®Google Scholar
• McEvoyJPLiebermanJAPerkinsDOEfficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparisonAm J Psychiatry200716471050106017606657
   PubMed Web of Science ®Google Scholar
• PerkinsDOGuHWeidenPJMcEvoyJPHamerRMLiebermanJAPredictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter studyJ Clin Psychiatry200869110611318312044
   PubMed Web of Science ®Google Scholar
• NasrallahHATargumSDTandonRMcCombsJSRossRDefining and measuring clinical effectiveness in the treatment of schizophreniaPsychiatr Serv200556327328215746501
   PubMed Web of Science ®Google Scholar
• KinonBJChenLAscher-SvanumHChallenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophreniaSchizophr Res20101181–317618220080036
   PubMed Web of Science ®Google Scholar
• StaufferVLCaseMKinonBJEarly response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosisPsychiatry Res20111871–2424821168920
   PubMed Web of Science ®Google Scholar
• GieglingIPorcelliSBalzarroBAntipsychotic response in the first week predicts later efficacyNeuropsychobiology201266210010522814310
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDELacroJPDolderCRPengXAdherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophreniaPatient Prefer Adherence20082677719920946
   PubMedGoogle Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
   PubMed Web of Science ®Google Scholar
• AndreasenNCCarpenterWTJrKaneJMLasserRAMarderSRWeinbergerDRRemission in schizophrenia: proposed criteria and rationale for consensusAm J Psychiatry2005162344144915741458
   PubMed Web of Science ®Google Scholar
• EmsleyROosthuizenPKoenLNiehausDJMedoriRRabinowitzJRemission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injectionInt Clin Psychopharmacol200823632533118854720
   PubMed Web of Science ®Google Scholar
• LaurielloJLambertTAndersonSLinDTaylorCCMcDonnellDAn 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophreniaJ Clin Psychiatry20086979079918452346
   PubMed Web of Science ®Google Scholar
• KaneJMSanchezRPerryPPAripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry20127361762422697189
   PubMed Web of Science ®Google Scholar
• PotkinSGWeidenPJLoebelADWarringtonLEWatskyEJSiuCORemission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs haloperidolInt J Neuropsychopharmacol20091291233124819419595
   PubMed Web of Science ®Google Scholar
• GorwoodPPeuskensJEuropean Group On Functional Outcomes, Remission in SchizophreniaSetting new standards in schizophrenia outcomes: Symptomatic remission 3 years before versus after the andreasen criteriaEur Psychiatry201227317017521641777
   PubMed Web of Science ®Google Scholar
• LambertMKarowALeuchtSSchimmelmannBGNaberDRemission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years laterDialogues Clin Neurosci201012339340720954433
   PubMedGoogle Scholar
• AlAqeelBMargoleseHCRemission in schizophrenia: critical and systematic reviewHarv Rev Psychiatry20122028129723216066
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• HamiltonMDevelopment of a rating scale for primary depressive illnessBr J Soc Clin Psychol1967642782966080235
   PubMedGoogle Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
   PubMed Web of Science ®Google Scholar
• AddingtonDAddingtonJMaticka-TyndaleEAssessing depression in schizophrenia: the Calgary Depression ScaleBr J Psychiatry Suppl19932239448110442
   PubMedGoogle Scholar
• HoferARettenbacherMAEdlingerMOutcomes in schizophrenia outpatients treated with amisulpride or olanzapinePharmacopsychiatry20074011817327953
   PubMed Web of Science ®Google Scholar
• KahnRSSchulzSCPalazovVDEfficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768683284217592906
   PubMed Web of Science ®Google Scholar
• MeltzerHYBoboWVNuamahIFEfficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studiesJ Clin Psychiatry200869581782918466043
   PubMed Web of Science ®Google Scholar
• KeefeRSBilderRMDavisSMNeurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE TrialArch Gen Psychiatry200764663364717548746
   PubMed Web of Science ®Google Scholar
• KeefeRSPoeMWalkerTMKangJWHarveyPDThe Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacityAm J Psychiatry2006163342643216513863
   PubMed Web of Science ®Google Scholar
• GalderisiSDavidsonMKahnRSCorrelates of cognitive impairment in first episode schizophrenia: the EUFEST studySchizophr Res20091152–310411419822407
   PubMed Web of Science ®Google Scholar
• MausbachBTDeppCABowieCRSensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophreniaSchizophr Res20111322–316517021843926
   PubMed Web of Science ®Google Scholar
• NuechterleinKHGreenMFKernRSThe MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validityAm J Psychiatry2008165220321318172019
   PubMed Web of Science ®Google Scholar
• KeefeRSGoldbergTEHarveyPDGoldJMPoeMPCoughenourLThe Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive batterySchizophr Res2004682–328329715099610
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKisslingWPsychoeducation for patients with schizophrenia and their familiesExpert Rev Neurother2008871067107718590477
   PubMedGoogle Scholar
• LarsenDLAttkissonCCHargreavesWANguyenTDAssessment of client/patient satisfaction: development of a general scaleEval Program Plann19792319720710245370
   PubMedGoogle Scholar
• RuggeriMLasalviaADall’AgnolaRDevelopment, internal consistency and reliability of the Verona Service Satisfaction Scale – European Version. EPSILON Study 7. European Psychiatric Services: Inputs Linked to Outcome Domains and NeedsBr J Psychiatry Suppl200039s41s4810945077
   PubMedGoogle Scholar
• RichardsonMKatsakouCTorres-GonzalezFOnchevGKallertTPriebeSFactorial validity and measurement equivalence of the Client Assessment of Treatment Scale for psychiatric inpatient care – a study in three European countriesPsychiatry Res2011188115616021342706
   PubMed Web of Science ®Google Scholar
• EndicottJNeeJHarrisonWBlumenthalRQuality of Life Enjoyment and Satisfaction Questionnaire: a new measurePsychopharmacol Bull19932923213268290681
   PubMed Web of Science ®Google Scholar
• AtkinsonMJSinhaAHassSLValidation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth Qual Life Outcomes200421214987333
   PubMedGoogle Scholar
• GharabawiGMGreenspanARupnowMFReduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trialBMC Psychiatry200664517054789
   PubMed Web of Science ®Google Scholar
• VernonMKRevickiDAAwadAGPsychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patientsSchizophr Res20101181–327127820172695
   PubMed Web of Science ®Google Scholar
• JuckelGMorosiniPLThe new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophreniaCurr Opin Psychiatry200821663063918852573
   PubMed Web of Science ®Google Scholar
• GalderisiSMucciABitterIPersistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia TrialEur Neuropsychopharmacol20132319620422647933
   PubMed Web of Science ®Google Scholar
• MorganCBurnsTFitzpatrickRPinfoldVPriebeSSocial exclusion and mental health: conceptual and methodological reviewBr J Psychiatry200719147748318055950
   PubMed Web of Science ®Google Scholar
• PatrickDLBurnsTMorosiniPGagnonDDRothmanMAdriaenssenIMeasuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tabletsClin Ther201032227529220206786
   PubMed Web of Science ®Google Scholar
• MosolovSNPotapovAVUshakovUVRemission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient populationAnn Gen Psychiatry201211122221826
   PubMed Web of Science ®Google Scholar
• MosolovSNPotapovAVUshakovUVShararenkoAAKostyukovaABDesign and validation of standardized clinical and functional remission criteria in schizophreniaNeuropsychiatr Dis Treat20141016718124511232
   PubMed Web of Science ®Google Scholar
• KarowANaberDLambertMMoritzSEGOFORS initiativeRemission as perceived by people with schizophrenia, family members and psychiatristsEur Psychiatry201227642643121571506
   PubMed Web of Science ®Google Scholar
• MorosiniPLMaglianoLBrambillaLUgoliniSPioliRDevelopment, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioningActa Psychiatr Scand2000101432332910782554
   PubMed Web of Science ®Google Scholar
• NafeesBvan Hanswijck de JongePStullDReliability and validity of the Personal and Social Performance scale in patients with schizophreniaSchizophr Res20121401–3717622749622
   PubMed Web of Science ®Google Scholar
• BrissosSPalhavaFMarquesJGThe Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patientsSoc Psychiatry Psychiatr Epidemiol20124771077108621739224
   PubMed Web of Science ®Google Scholar
• TianmeiSLiangSYun’aiSThe Chinese version of the Personal and Social Performance Scale (PSP): validity and reliabilityPsychiatry Res20111851–227527920542575
   PubMed Web of Science ®Google Scholar
• ApiquianRElenaURHerrera-EstrellaMValidity of the Spanish version of the Personal and Social Performance scale in schizophreniaSchizophr Res20091121–318118619398302
   PubMed Web of Science ®Google Scholar
• NasrallahHMorosiniPGagnonDDReliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophreniaPsychiatry Res2008161221322418848731
   PubMed Web of Science ®Google Scholar
• PatrickDLBurnsTMorosiniPReliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophreniaCurr Med Res Opin200925232533819192977
   PubMed Web of Science ®Google Scholar
• FigueiraMLBrissosSMeasuring psychosocial outcomes in schizophrenia patientsCurr Opin Psychiatry201124919921285701
   PubMed Web of Science ®Google Scholar
• Mendes MenzesAKMacedoGMattosPReis de Sá JúniorALouzaMRPersonal and Social Performance (PSP) scale for patients with schizophrenia: translation to Portuguese, cross-cultural adaption and interrater reliabilityJ Bras Psiquiatr201261176180
   Google Scholar
• JuckelGSchaubDFuchsNValidation of the Personal and Social Performance (PSP) Scale in a German sample of acutely ill patients with schizophreniaSchizophr Res20081041–328729318595665
   PubMed Web of Science ®Google Scholar
• SrisurapontMArunpongpaisalSChuntaruchikapongSCross-cultural validation and inter-rater reliability of the Personal and Social Performance Scale, Thai VersionJ Med Assoc Thai2008911603160818972906
   PubMedGoogle Scholar
• BurnsTPatrickDSocial functioning as an outcome measure in schizophrenia studiesActa Psychiatr Scand2007116640341817941964
   PubMed Web of Science ®Google Scholar
• SchaubDBrüneMBierhoffHWJuckelGComparison of self- and clinician’s ratings of Personal and Social Performance in patients with schizophrenia: the role of insightPsychopathology201245210911622310493
   PubMed Web of Science ®Google Scholar
• SchaubDBrüneMJaspenEPajonkFGBierhoffHWJuckelGThe illness and everyday living: close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophreniaEur Arch Psychiatry Clin Neurosci20112612859320652295
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar